{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-23-000037","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.890864+00:00","generated_at":"2026-06-15T14:09:30.228678+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Maravai Q1 revenue $79M, down 68% YoY; net loss $1.3M vs prior net income $146.9M","bullets":["Revenue $79.0M, -67.7% YoY; net loss $(1.3)M vs net income $146.9M in Q1 2022.","Nucleic Acid Production revenue $61.5M (-72.5% YoY) includes ~$15.9M COVID-19 CleanCap revenue, $157M less YoY.","Biologics Safety Testing revenue $17.6M (-14.9% YoY) driven by post-COVID inventory normalization and China slowdown.","Adjusted EBITDA $23.8M (30.1% margin), down from $187.0M in prior year."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-23-000037","json":"https://secwatch.observer/filing/0001823239-23-000037.json","markdown":"https://secwatch.observer/filing/0001823239-23-000037.md","text":"https://secwatch.observer/filing/0001823239-23-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000037/0001823239-23-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000037/mrvi-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T14:09:30.228678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69e745d1e758c2044b9395bde78d51afe4aa1ad2","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported the first quarter ended March 31, 2023 results: revenue $79.0 million, net income $(1.3) million.","evidence_excerpt":"Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2023, together with other business updates. Recent highlights include: • Quarterly revenue of $79.0 million, Net loss of $(1.3) million, and Adjusted EBITDA margins of 30.1%;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000037/0001823239-23-000037-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$79.0 million"},{"label":"Net income","value":"$(1.3) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}